Updates from Syncona and our portfolio companies
Freeline is pleased to announce the appointment of Brian M. Silver as Chief Financial Officer and Head of Corporate Development. Brian will be based in New York, as the Company establishes offices in the United States.
Freeline will develop a ‘next-generation’ therapy platform at the Cell and Gene Therapy Catapult’s UK-based large-scale GMP manufacturing centre. Company will further develop proprietary viral vector manufacturing technology for bleeding and other disorders.
Freeline Therapeutics (“Freeline”), a biopharmaceutical company focused on the development of curative gene therapies for bleeding and other debilitating disorders, today announced that Anne Prener has been appointed Chief Executive Officer.